Add to ORKGThe use of high-efficacy disease-modifying therapies (DMTs) early in the course of multiple sclerosis (MS) has been shown to improve clinical outcomes and is becoming an increasingly popular treatment strategy. As a result, monoclonal antibodies, including natalizumab, alemtuzumab, ocrelizumab, ofatumumab, and ublituximab, are frequently used for the treatment of MS in women of childbearing age. To date, only limited evidence is available on the use of these DMTs in pregnancy. We aim to provide an updated overview of the mechanisms of action, risks of exposure and treatment withdrawal, and pre-conception counseling and management during pregnancy and post-partum of monoclonal antibodies in women with MS. Discussing treatment options and fam...
Although pregnancy in women with multiple sclerosis (MS) is not generally considered high risk, ther...
International audienceBACKGROUND: In Multiple Sclerosis (MS) women, therapeutic management for pregn...
International audienceMultiple sclerosis (MS) is usually diagnosed between twenty and forty years of...
The burden of multiple sclerosis (MS) in women of childbearing potential is increasing, with peak in...
Abstract Most disease-modifying drugs (DMDs) are contraindicated in pregnancy. Management of MS is e...
Pregnancy rates are rapidly increasing among women of reproductive age diagnosed with multiple scler...
PURPOSE OF THE REVIEW: To provide the latest evidence and treatment advances of multiple sclerosis i...
\(\textbf {Background:}\) The incidence of multiple sclerosis (MS) is increasing, particularly in yo...
Background and objective: Women with multiple sclerosis (MS) who intend to get pregnant are often ad...
Abstract Objective Postpartum, patients with multiple sclerosis (MS) and neuromyelitis optica spectr...
Although pregnancy in women with multiple sclerosis (MS) is not generally considered high risk, ther...
Multiple sclerosis (MS) is a common inflammatory demyelinating disorder of the central nervous syste...
BACKGROUND: In current literature, no data on safety in pregnancy for new drugs in the treatment of ...
Multiple sclerosis (MS) is a demyelinating and neurodegenerative disease of the central nervous syst...
Although pregnancy in women with multiple sclerosis (MS) is not generally considered high risk, ther...
International audienceBACKGROUND: In Multiple Sclerosis (MS) women, therapeutic management for pregn...
International audienceMultiple sclerosis (MS) is usually diagnosed between twenty and forty years of...
The burden of multiple sclerosis (MS) in women of childbearing potential is increasing, with peak in...
Abstract Most disease-modifying drugs (DMDs) are contraindicated in pregnancy. Management of MS is e...
Pregnancy rates are rapidly increasing among women of reproductive age diagnosed with multiple scler...
PURPOSE OF THE REVIEW: To provide the latest evidence and treatment advances of multiple sclerosis i...
\(\textbf {Background:}\) The incidence of multiple sclerosis (MS) is increasing, particularly in yo...
Background and objective: Women with multiple sclerosis (MS) who intend to get pregnant are often ad...
Abstract Objective Postpartum, patients with multiple sclerosis (MS) and neuromyelitis optica spectr...
Although pregnancy in women with multiple sclerosis (MS) is not generally considered high risk, ther...
Multiple sclerosis (MS) is a common inflammatory demyelinating disorder of the central nervous syste...
BACKGROUND: In current literature, no data on safety in pregnancy for new drugs in the treatment of ...
Multiple sclerosis (MS) is a demyelinating and neurodegenerative disease of the central nervous syst...
Although pregnancy in women with multiple sclerosis (MS) is not generally considered high risk, ther...
International audienceBACKGROUND: In Multiple Sclerosis (MS) women, therapeutic management for pregn...
International audienceMultiple sclerosis (MS) is usually diagnosed between twenty and forty years of...